The Lancet13h
Management and mechanisms of eosinophil action in asthma: mind the gap?
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
Smaller biotechs see new mechanisms of actions as future of obesity treatments
Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...
Palatin Technologies, Inc.: Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Medscape5d
Some Patients — And Doctors — Turn to Microdosing GLP-1s
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Taiwan News6d
Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy on VSDHOne Platform
NAD+ IonToPatch – Utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption. The latex ...